{
  "pmcid": "11848233",
  "sha256": "697acf22d0889aaf0932ad0d1b5b100817d9d11aaf6c9f99daf845b0b75a2830",
  "timestamp_utc": "2025-11-09T22:09:20.008186+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.71261244769875,
    "reading_ease": 37.69435800209206,
    "word_count": 239
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Plasma Expansion on Renal Perfusion in Critically Ill COVID-19 Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were ICU-treated COVID-19 patients without underlying kidney disease, assigned to AKI or NO AKI groups based on KDIGO Creatinine criteria."
      },
      "Participants": {
        "score": 1,
        "evidence": "Participants were ICU-treated COVID-19 patients without underlying kidney disease"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Renal perfusion was assessed using magnetic resonance imaging before and after plasma expansion with 7.5 mL/kg Ringer's Acetate."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effects of plasma expansion with a standardized fluid bolus on renal perfusion in critically ill COVID-19 patients with and without acute kidney injury (AKI)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in renal perfusion, measured immediately post-intervention."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Seventeen patients were enrolled between June 4, 2020, and May 10, 2021, with nine in the AKI group and eight in the NO AKI group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Seventeen patients were enrolled between June 4, 2020, and May 10, 2021, with nine in the AKI group and eight in the NO AKI group."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Plasma expansion increased mean arterial pressure by 9 mmHg (95% CI 0.5–18) in the AKI group and 15 mmHg (95% CI 5–24) in the NO AKI group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials ID: NCT02765191."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by Uppsala University Hospital and other grants."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}